Moody's Ratings (Moody's) assigned a B1 rating to the new backed senior unsecured notes that Carnival Corporation (Carnival) announced earlier today. The Notes will be guaranteed by the same subsidiaries that guarantee the company's other unsecured notes. Carnival will use the net proceeds to redeem...
Capricor Therapeutics to Participate in Upcoming Investor Conferences SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to participate in the following upcoming investor conferences. Event:Oppenheimer 35thAnnual Healthcare Life Sciences Conference (Virtual)Date:February 12, 2025 from 12:00-12:30 p.m. ETWebcast Link Event:Barclays 27thAnnual Global Healthcare Conference (Miami, FL)Date:March 11-13, 2025 Event:3...
Moody's Ratings (Moody's) assigned a B2 rating to the new backed senior unsecured notes (Notes) that Carnival Corporation (Carnival) announced earlier today. The Notes will be guaranteed by the same subsidiaries that guarantee the company's other unsecured notes. Carnival will use the net proceeds p...
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy -If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of the submission of its...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.